LEMTRADA (Alemtuzumab)- Only FDA approved drug of November- 2014
TRADE (BRAND) NAME- LEMTRADA
ACTIVE PHARMACEUTICAL INGREDIENT- Alemtuzumab
COMPANY- Genzyme
USE- Treatment of T-cell lymphoma and chronic lymphocytic leukemia
Alemtuzumab has been in use for the above diseases from a long time ago. In 2008 ,at Cambridge University, it was suggested that it can be used in the treatment of relapsing multiple sclerosis (MS) and also reversing its effects. But it was not approved by FDA due to lack of solid proof and results in treating multiple sclerosis. However, thanks to the persistent fight by Genzyme, it was finally granted FDA approval in November 2014.
It is a humanized monoclonal antibody obtained from rat. It attacks CD52 protein present on T- and B- cells. The inflammatory responses observed in MS were due to the abundance of T- and B-cells and alemtuzumab depletes these cells after every dose. However, it is used as a secondary choice of drug in MS therapy due to its low safety profile. Various life-threatening side effects include auto-immune disorders, prone to malignancies like thyroid cancer. rashes, fatigue etc. are observed with alemtuzumab.
- Darwin
TRADE (BRAND) NAME- LEMTRADA
ACTIVE PHARMACEUTICAL INGREDIENT- Alemtuzumab
COMPANY- Genzyme
USE- Treatment of T-cell lymphoma and chronic lymphocytic leukemia
Alemtuzumab has been in use for the above diseases from a long time ago. In 2008 ,at Cambridge University, it was suggested that it can be used in the treatment of relapsing multiple sclerosis (MS) and also reversing its effects. But it was not approved by FDA due to lack of solid proof and results in treating multiple sclerosis. However, thanks to the persistent fight by Genzyme, it was finally granted FDA approval in November 2014.
It is a humanized monoclonal antibody obtained from rat. It attacks CD52 protein present on T- and B- cells. The inflammatory responses observed in MS were due to the abundance of T- and B-cells and alemtuzumab depletes these cells after every dose. However, it is used as a secondary choice of drug in MS therapy due to its low safety profile. Various life-threatening side effects include auto-immune disorders, prone to malignancies like thyroid cancer. rashes, fatigue etc. are observed with alemtuzumab.
- Darwin
No comments:
Post a Comment